Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $2.8 million.

  • Myriad Genetics' Capital Expenditures fell 2000.0% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year decrease of 4291.34%. This contributed to the annual value of $19.0 million for FY2024, which is 6993.67% down from last year.
  • Per Myriad Genetics' latest filing, its Capital Expenditures stood at $2.8 million for Q3 2025, which was down 2000.0% from $2.8 million recorded in Q2 2025.
  • Myriad Genetics' Capital Expenditures' 5-year high stood at $23.5 million during Q1 2023, with a 5-year trough of $2.8 million in Q2 2025.
  • For the 5-year period, Myriad Genetics' Capital Expenditures averaged around $8.2 million, with its median value being $6.3 million (2022).
  • Per our database at Business Quant, Myriad Genetics' Capital Expenditures soared by 49000.0% in 2022 and then crashed by 7234.04% in 2024.
  • Quarter analysis of 5 years shows Myriad Genetics' Capital Expenditures stood at $3.4 million in 2021, then skyrocketed by 329.41% to $14.6 million in 2022, then plummeted by 31.51% to $10.0 million in 2023, then crashed by 64.0% to $3.6 million in 2024, then fell by 22.22% to $2.8 million in 2025.
  • Its Capital Expenditures stands at $2.8 million for Q3 2025, versus $2.8 million for Q2 2025 and $5.3 million for Q1 2025.